Is Childhood Leukemia Curable? What Parents Should Know

Childhood leukemia is one of the great success stories in cancer medicine. Five-year survival for the most common type, acute lymphoblastic leukemia (ALL), has risen from less than 10 percent in the 1960s to roughly 90 percent today in high-income countries. For children who reach and stay in remission for several years after finishing treatment, the chance of the disease ever returning drops below one percent, which is as close to a definitive cure as oncology gets. But the word “curable” carries important caveats that depend on the type of leukemia, how early and aggressively it is treated, and where in the world a child lives.

What “Cured” Actually Means

Oncologists are careful with the word “cure” because cancer can, in theory, return years after treatment ends. For childhood ALL, researchers have established a practical threshold: children who complete contemporary chemotherapy and remain in remission for four years after finishing treatment have less than a one percent chance of relapse. At that point, they are considered cured in the medical sense.¹ A similar analysis for acute myeloid leukemia (AML) found that children with AML who stay in remission four years from diagnosis have also likely been cured.²

Reaching that four-year mark is the challenge. About six percent of children with ALL relapse after completing treatment, meaning that while the vast majority are cured, a meaningful minority face a second round of therapy.¹ For AML, the road is harder, as the next section explains.

ALL and AML Are Not the Same Disease

About 80 percent of childhood leukemias are ALL, and this is the type behind the encouraging survival statistics most parents encounter. AML accounts for most of the rest, and it behaves differently. Treatment for AML is more intensive, remission is harder to achieve, and treatment-related deaths are more common. A Dutch study found that nearly one in five children with AML on their protocols died from causes other than resistant disease or relapse, compared with about one in forty children with ALL.³

Survival for childhood AML has also improved over the decades but still lags well behind ALL. International data show wide variation by country: five-year survival for AML ranged from single digits in some registries to above 70 percent in the best-performing ones during the 2005-2009 period.⁴ When parents hear that childhood leukemia is “curable,” they should know that the optimistic numbers refer primarily to ALL. AML is curable too, but the odds are lower and the treatment is rougher.

How Treatment Is Structured

Treatment for childhood ALL typically stretches over two to three years and unfolds in phases. It starts with an intensive induction phase, usually lasting about a month, aimed at wiping out the bulk of leukemia cells and achieving complete remission. This is followed by consolidation, which targets any remaining cancer that survived induction. Finally, a prolonged maintenance phase of lower-intensity chemotherapy works to prevent late relapse.⁵ Throughout treatment, children also receive drugs aimed at preventing leukemia from spreading to the central nervous system, delivered both through the bloodstream and directly into the spinal fluid.

The overall framework has remained remarkably consistent for decades, though the specific drugs and their doses have been refined through successive clinical trials. In high-income countries, chemotherapy alone produces survival rates in the range of 85 to 90 percent for ALL.⁶ AML treatment follows a broadly similar phased approach but typically uses different, more aggressive drug combinations, and the maintenance phase is shorter or absent.

How Doctors Determine Your Child’s Risk Level

Not every child with ALL faces the same odds. Early in treatment, oncologists assign a risk category that determines how intensive the rest of treatment will be. Age at diagnosis, white blood cell count, and certain genetic features of the leukemia cells all play a role.⁷ But the single most powerful predictor of outcome is something measured during treatment itself: minimal residual disease, or MRD. This is a lab test that detects tiny traces of leukemia cells that are invisible under a standard microscope.

A large Children’s Oncology Group study of over 2,100 children with ALL found that MRD measured at the end of induction was the most important predictor of relapse in a head-to-head comparison against every other known risk factor. Children with even very low but detectable MRD at that time point had five-year event-free survival of about 59 percent, compared with 88 percent for those whose MRD was undetectable.⁸ Earlier work from St. Jude established that MRD detection retains prognostic significance even later in treatment: any detectable disease at 12 or 24 months from diagnosis was highly predictive of relapse.⁹

On the encouraging side, the roughly 12 percent of children in the COG study who had every favorable factor, including low-risk genetics and undetectable MRD at both early time points, had a five-year event-free survival of 97 percent with relatively non-intensive therapy.⁸ For these children, the goal is shifting toward giving less treatment and reducing long-term side effects while preserving those excellent cure rates.

When Leukemia Comes Back

Relapse is the outcome every parent fears, and while it is far less common than it used to be, it still occurs. In a single-institution review, the median time from diagnosis to relapse was about 29 months. Timing matters greatly for prognosis: early relapse, occurring during or shortly after treatment, is biologically more aggressive and harder to treat than late relapse.¹⁰ Where the disease returns also matters. A Children’s Oncology Group study of children with late bone marrow relapse or very early isolated central nervous system relapse showed that outcomes varied sharply by site, with early CNS relapse carrying a three-year event-free survival of only about 41 percent.¹¹

Relapsed leukemia is not a death sentence, but it changes the conversation. Treatment becomes more intensive, and newer therapies often enter the picture.

Newer Therapies for Hard-to-Treat Cases

Over the past decade, a wave of targeted and immune-based therapies has expanded the toolkit for children whose leukemia does not respond to standard chemotherapy or who relapse. These include bispecific antibodies like blinatumomab, antibody-drug conjugates like inotuzumab ozogamicin, and monoclonal antibodies such as daratumumab.¹² For children with Philadelphia chromosome-positive ALL or the related “Ph-like” subtype, tyrosine kinase inhibitors have added a targeted weapon to chemotherapy backbones.¹³

The most dramatic newcomer is CAR-T cell therapy, in which a child’s own immune cells are re-engineered in a lab to recognize and attack leukemia. In children with relapsed or treatment-resistant B-cell ALL, CAR-T therapy targeting CD19 produces complete remission in 80 to 90 percent of cases.¹⁴ That initial response is impressive, but durability remains a challenge: roughly half of responding patients relapse again within one to two years after CAR-T therapy. For many of these children, the remission achieved by CAR-T buys time to proceed to a stem cell transplant, which offers longer-lasting control. In one long-term follow-up study, children who achieved remission with CAR-T and then received a transplant had a five-year event-free survival of about 62 percent.¹⁵

Stem cell transplant itself carries significant risks. A large Italian registry study of high-risk ALL children transplanted in first remission reported ten-year overall survival of about 63 percent, with transplant-related deaths accounting for 15 percent of patients.¹⁶ These are reserved for children whose disease profile suggests chemotherapy alone is unlikely to be enough.

Subgroups That Face Tougher Odds

Infant ALL is biologically distinct from the disease in older children and among the hardest to cure. It accounts for less than five percent of pediatric ALL cases but carries an outsized share of treatment failures. About 70 to 80 percent of infant cases involve a specific genetic rearrangement called KMT2A, which drives an aggressive form of the disease.¹⁷ Decades of intensifying chemotherapy have yielded only modest improvements for this group, and research is actively exploring immunotherapy and targeted approaches to change the calculus.

Adolescents and young adults also tend to fare worse than children between roughly two and ten years old, who represent the age band with the best outcomes. Part of this relates to the biology of the leukemia cells at different ages, and part relates to treatment adherence and access during the teenage years.

Late Effects That Survivors Live With

Curing leukemia is not the end of the story. The treatments that save children’s lives can leave lasting marks on growing bodies. Survivors of childhood ALL face elevated risks of secondary cancers, heart damage from certain chemotherapy drugs, bone weakening, liver problems, obesity, fertility issues, and lung function deficits.¹⁸ One study of long-term adult survivors treated with chemotherapy only found that over 40 percent had impaired cardiorespiratory fitness, with those exposed to anthracycline drugs showing lower heart function than those who were not.¹⁹

Neurocognitive effects are a particular concern for parents. Cranial radiation, once standard, was largely replaced by intrathecal chemotherapy precisely because radiation caused severe cognitive problems.²⁰ The shift helped, but chemotherapy-only protocols still carry some neurocognitive risk. One study found that children who received radiation had smaller brain structures and worse cognitive scores than both chemotherapy-only patients and healthy controls, while the chemotherapy-only group had brain volumes similar to controls but still showed some cognitive effects.²¹ Among children who did receive radiation plus chemotherapy, over 80 percent experienced delayed neurological or cognitive problems compared to healthy siblings.²²

These late effects are why survivorship care is not optional. Children who finish treatment should continue to be monitored for heart health, cognitive development, hormone levels, and secondary cancers for years and sometimes for life.

The Emotional and Financial Toll on Families

A childhood leukemia diagnosis is a psychological earthquake for the entire family. Research tracking mothers of children with leukemia during the first 12 months of treatment found elevated stress symptoms, particularly in the early weeks after diagnosis.²³ Most parents do recover emotionally over time: a study of parents of long-term ALL survivors found that, on average, clinically significant depression and anxiety were uncommon years after treatment ended. However, about 28 percent still reported intrusive thoughts related to the cancer experience, and a small subset, roughly four percent, had globally elevated post-traumatic stress symptoms even years later.²⁴

Financial strain is the other hidden wound. Treatment spans years, often requiring a parent to reduce work hours or stop working altogether. One study found that by 24 months into treatment, about 30 percent of families experienced serious material hardship and roughly 32 percent suffered catastrophic income loss. Families already near the poverty line, single-parent households, and non-English-speaking households were disproportionately affected. Parents should know that many pediatric oncology centers have social workers and financial navigators, and asking for help early is far better than waiting until bills pile up.

Where You Live Changes the Odds

The survival figures quoted throughout this article reflect what is achievable in well-resourced healthcare systems. Globally, the picture is starkly different. Roughly 80 percent of childhood leukemia cases occur in low- and middle-income countries, where survival for ALL can be as low as 20 to 40 percent, compared to over 85 percent in high-income settings.²⁵ The gap is driven by delayed diagnosis, limited access to chemotherapy drugs, underfunded supportive care, and higher rates of treatment abandonment.

International data confirm that while survival has risen in every region, the gap between the richest and poorest countries persists. Adolescents do worse than younger children worldwide, and this age-based disparity is even sharper in lower-income settings.²⁶ Programs adapted for resource-limited settings, focusing on locally affordable drug regimens and family support to reduce treatment abandonment, represent the area where the largest global gains in childhood leukemia survival are still to be made.

Growing Up After Leukemia

Children cured of leukemia eventually become adults who need ongoing monitoring for the late effects described above. Yet the transition from pediatric oncology follow-up to adult survivorship care is poorly structured at most institutions. A survey of Children’s Oncology Group centers found that only about a quarter had a written transition policy, only a third incorporated readiness assessments into practice, and fewer than one in ten systematically collected feedback from young adults about the transition experience.²⁷ On average, institutions offered just one of six recommended transition services.

For parents, this means that advocating for a clear transition plan should start well before your child ages out of pediatric care. A detailed treatment summary, a written plan for long-term monitoring of heart function, fertility, and cognitive health, and an identified adult provider who understands childhood cancer survivorship are all things worth asking about early. The pediatric oncology team treats the cancer. Preparing the child for lifelong health afterward requires a different kind of planning that too few centers currently provide well.